Identifying genes linked to familial pituitary adenomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research aims to discover new predisposition genes associated with endocrine tumors, particularly focusing on pituitary adenomas such as acromegaly and gigantism. Patients will be recruited from various Endocrine outpatient clinics and inpatient wards, with an emphasis on those showing evidence of hereditary conditions. The study will investigate the role of the AIP gene and its interactions in the development of familial and sporadic pituitary tumors. By understanding these genetic factors, the research seeks to shed light on the mechanisms behind pituitary tumorigenesis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Familial acromegaly or other type of pituitary tumour OR
* Early onset acromegaly or
* Sporadic pituitary tumour

Exclusion Criteria:

* Do not consent

Where it's running

• Leicester Infirmary
  Leicester, United Kingdom Recruiting
• Barts and the London medical School
  London, United Kingdom Recruiting
• Royal Victoria Infirmary
  Newcastle upon Tyne, United Kingdom Recruiting

Study contacts

• Principal investigator: Marta Korbonits, MD PhD — Barts and the London Medical School
• Study coordinator: Marta Korbonits, MD PhD
• Email: m.korbonits@qmul.ac.uk
• Phone: 020 7882 6238

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NTQ6179 tablets first-in-human test in healthy adults

  This phase 1 study tests a single oral dose of NTQ6179 vs placebo in healthy adults to see if it is safe and how the body processes the drug.

  Recruiting Phase 1 Nanjing Chia-tai Tianqing Pharmaceutical · Beijing · NCT07909837

• Test MAR002 for acromegaly in adults on or off medical therapy

  This study tests whether subcutaneous MAR002 is safe and tolerable in adults with acromegaly, compared with a placebo, over 10 weeks.

  Recruiting at 3 sites Phase 2 Marea Therapeutics · Phoenix, Arizona and 2 other locations · NCT07641179

• Octreotide SC Depot in Acromegaly: Real-World Safety and Effectiveness

  This study follows people with acromegaly who are using octreotide subcutaneous depot to see how it works and how safe it is over up to two years in everyday clinical practice.

  Recruiting at 4 sites Camurus AB · Aachen and 6 other locations · NCT07583563

• MAR002 in healthy men

  This trial tests whether a subcutaneous injection of MAR002 is safe and tolerable in healthy men aged 18 to 40.

  Recruiting Phase 1 Marea Therapeutics · Tempe, Arizona · NCT07195175

• Pasireotide LAR and bone health in adults with acromegaly

  This study will test whether switching adults with uncontrolled acromegaly to pasireotide LAR changes bone turnover and the risk of vertebral fractures.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, RM · NCT07179926

• Assessing Debio 4126 for treating acromegaly in patients on somatostatin analogs

  This study is testing if a new treatment called Debio 4126 can help people with acromegaly who are already on somatostatin analogs keep their IGF-1 levels in check better than a placebo.

  Recruiting at 72 sites Phase 3 Debiopharm International SA · Los Angeles, California and 73 other locations · NCT06930625

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.